Vibrio parahaemolyticus bacteriophage Vib-PAP-4 and use thereof in inhibiting proliferation of Vibrio parahaemoliticus bacteria
Inventors
Yoon, Seong Jun • JUN, Soo Youn • KWON, An Sung • Song, Hyun Min • Hwang, Soon Hye • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11679137-B2
Publication Date
2023-06-20
Expiration Date
Abstract
The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.
Core Innovation
The document describes a Myoviridae bacteriophage designated as Vib-PAP-4, having a genome represented by SEQ ID NO:1 and deposited in the Korean Collection for Type Cultures under accession number KCTC 13168BP. Vib-PAP-4 is described as having an ability to specifically kill Vibrio parahaemolyticus strains and to act against vibriosis caused by Vibrio parahaemolyticus infection.
The core technical concept is a composition in which maltodextrin and proliferated and purified Myoviridae bacteriophage Vib-PAP-4 are provided as a dried mixture. The composition contains Vib-PAP-4 at 1×10^4 to 1×10^15 plaque-forming units per gram (pfu/g) in the dried mixture, and is presented as a way to block infection, inhibit disease development, suppress disease, or alleviate the pathological condition.
The document further reports that Vib-PAP-4 is characterized for selectivity and novelty through genome/novelty determination approaches including NGS, BLAST homology analysis, and open reading frame (ORF) comparison. Anti-infection performance is reported using plaque/spot assay and OD growth inhibition in vitro, and prophylactic and post-infection assessment in juvenile sea bass, including evaluation with a body darkening index and mortality outcomes.
Claims Coverage
The partial content provides one independent claim (clm-00001) that covers a dried-mixture composition for blocking or alleviating Vibrio parahaemolyticus infection-associated disease and pathology. The claim includes multiple inventive features: a specific maltodextrin dried mixture, a specified dose range of a specific deposited Myoviridae bacteriophage with a specified genome representation, and the specific functional intent (blocking infection, inhibiting development, suppressing disease, alleviating pathology).
Dried mixture of maltodextrin and Vib-PAP-4
A composition in which maltodextrin and Myoviridae bacteriophage Vib-PAP-4 are in a dried mixture for blocking Vibrio parahaemolyticus infection, inhibiting development of diseases caused by the infection, suppressing diseases caused by the infection, or alleviating the pathological condition of the diseases.
Specified dose of deposited Vib-PAP-4
The composition comprises maltodextrin and 1×10^4 to 1×10^15 plaque-forming units per gram (pfu/g) of proliferated and purified Myoviridae bacteriophage Vib-PAP-4.
Selective killing and genome/identity for Vib-PAP-4
Vib-PAP-4 specifically kills Vibrio parahaemolyticus and has a genome represented by SEQ ID NO:1, deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 13168BP.
Across the single independent claim, the invention is directed to a dried mixture composition using maltodextrin and a specific deposited Myoviridae bacteriophage (Vib-PAP-4) defined by genome representation (SEQ ID NO:1) and identity (KCTC 13168BP). The claim further requires a specified pfu/g range of proliferated and purified phage and ties the composition to functional outcomes of blocking infection, inhibiting disease development, suppressing disease, or alleviating pathological conditions.
Stated Advantages
Claims selectivity for specifically killing Vibrio parahaemolyticus strains.
Blocking a Vibrio parahaemolyticus infection, inhibiting the development of diseases caused by the infection, suppressing diseases caused by the infection, or alleviating the pathological condition of the diseases.
Documented Applications
Preventing and treating Vibrio parahaemolyticus infection using a composition containing Myoviridae bacteriophage Vib-PAP-4 as an active ingredient.
Prophylactic and post-infection treatment use cases in juvenile sea bass, assessed by body darkening index and mortality outcomes.
Formulation and delivery concepts including feed additives and a medicine bath agent, including freeze-dried maltodextrin formulations.
Interested in licensing this patent?